166 related articles for article (PubMed ID: 35116626)
1. Diagnostic and prognostic role of BTA, NMP22, survivin and cytology in urothelial carcinoma.
Gong YW; Wang YR; Fan GR; Niu Q; Zhao YL; Wang H; Svatek R; Rodriguez R; Wang ZP
Transl Cancer Res; 2021 Jul; 10(7):3192-3205. PubMed ID: 35116626
[TBL] [Abstract][Full Text] [Related]
2. Urine Biomarkers for the Diagnosis of Bladder Cancer: a Network Meta-Analysis.
Dong Y; Zhang T; Li X; Yu F; Yu H; Shao S
Urol J; 2021 Sep; 18(6):623-632. PubMed ID: 34585369
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
4. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
5. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
Ecke TH; Meisl CJ; Schlomm T; Rabien A; Labonté F; Rong D; Hofbauer S; Friedersdorff F; Sommerfeldt L; Gagel N; Gössl A; Barski D; Otto T; Grunewald CM; Niegisch G; Hennig MJP; Kramer MW; Koch S; Roggisch J; Hallmann S; Weiß S; Waldner M; Graff J; Veltrup E; Linden F; Hake R; Eidt S; Wirtz RM
Urol Oncol; 2023 Dec; 41(12):484.e17-484.e26. PubMed ID: 37407421
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
Friedrich MG; Hellstern A; Hautmann SH; Graefen M; Conrad S; Huland E; Huland H
J Urol; 2002 Aug; 168(2):470-4. PubMed ID: 12131290
[TBL] [Abstract][Full Text] [Related]
7. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
9. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
10. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
[TBL] [Abstract][Full Text] [Related]
11. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
[TBL] [Abstract][Full Text] [Related]
12. Comparison of screening methods in the detection of bladder cancer.
Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
[TBL] [Abstract][Full Text] [Related]
13. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.
Shariat SF; Casella R; Khoddami SM; Hernandez G; Sulser T; Gasser TC; Lerner SP
J Urol; 2004 Feb; 171(2 Pt 1):626-30. PubMed ID: 14713774
[TBL] [Abstract][Full Text] [Related]
14. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.
Sharma S; Zippe CD; Pandrangi L; Nelson D; Agarwal A
J Urol; 1999 Jul; 162(1):53-7. PubMed ID: 10379739
[TBL] [Abstract][Full Text] [Related]
15. Tumor Location Based Segmentation in Upper-Tract Urothelial Carcinoma Impacts on the Urothelial Recurrence-Free Survival: A Multi-Institutional Database Study.
Inamoto T; Matsuyama H; Komura K; Ibuki N; Fujimoto K; Shiina H; Sakano S; Nagao K; Mastumoto H; Miyake M; Tatsumi Y; Yasumoto H; Azuma H
Curr Urol; 2020 Dec; 14(4):183-190. PubMed ID: 33488336
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury.
Davies B; Chen JJ; McMurry T; Landsittel D; Lewis N; Brenes G; Getzenberg RH
Urology; 2005 Oct; 66(4):908-11. PubMed ID: 16230180
[TBL] [Abstract][Full Text] [Related]
17. Human complement factor H related protein test for monitoring bladder cancer.
Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
[TBL] [Abstract][Full Text] [Related]
18. [Urinary tumor marker for urothelial cancer].
Ohtani M; Iwasaki A; Shiraiwa H
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.
Bell MD; Yafi FA; Brimo F; Steinberg J; Aprikian AG; Tanguay S; Kassouf W
World J Urol; 2016 Oct; 34(10):1405-9. PubMed ID: 26906030
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic efficacy of urinary survivin and hyaluronidase mRNA as urine markers in patients with bladder cancer.
Eissa S; Badr S; Barakat M; Zaghloul AS; Mohanad M
Clin Lab; 2013; 59(7-8):893-900. PubMed ID: 24133921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]